Hi synaphai, you said “So I think our large upcoming US pivotal trial will likely will serve both a US and Canada approval”. My post was more towards ViV, and I am thinking if a separate ViV study in Canada may bring to a quicker commercialisation approval of DurAVR in Canada. I recalled you might have mentioned a separate ViV trial maybe needed for FDA clearance?
Not advice and DYOR
Ann: Three ViV Patients Completed under Health Canada SAP, page-25
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
-0.300(1.64%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.29 | $18.30 | $17.65 | $181.7K | 10.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.00 | 499 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |